Cerevel Therapeutics Holdings, Inc. (CERE)
Company Info
Highlights
$8.19B
-$2.73
$38.50 - $44.99
$43.40
6.88%
2.37
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
Loading data...
Returns By Period
CERE
N/A
N/A
N/A
N/A
N/A
N/A
N/A
^GSPC (Benchmark)
0.51%
6.15%
-2.00%
12.92%
12.68%
14.19%
10.85%
Monthly Returns
The table below presents the monthly returns of CERE, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024 | -1.18% | -2.15% | 3.10% | 1.04% | -4.61% | 0.37% | 9.95% | 0.00% | 6.04% | ||||
| 2023 | 8.28% | -21.84% | -8.62% | 19.07% | 12.26% | -2.48% | -3.77% | -22.52% | -7.89% | 8.34% | 9.64% | 63.52% | 34.43% |
| 2022 | -19.68% | 1.65% | 32.26% | -16.37% | -10.76% | 1.19% | -0.57% | 10.69% | -2.89% | -1.06% | 3.58% | 8.91% | -2.71% |
| 2021 | -22.38% | 17.79% | -9.43% | 5.97% | -9.83% | 95.27% | -3.83% | 28.49% | -6.82% | 37.80% | -23.27% | 3.94% | 95.54% |
| 2020 | 4.25% | 37.09% | 17.42% | 67.81% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
With an overall rank of 97, CERE is among the top 3% of stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Cerevel Therapeutics Holdings, Inc. (CERE) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Loading data...
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading data...
Worst Drawdowns
The table below displays the maximum drawdowns of the Cerevel Therapeutics Holdings, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Cerevel Therapeutics Holdings, Inc. was 54.61%, occurring on Sep 22, 2023. Recovery took 214 trading sessions.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -54.61% | Nov 5, 2021 | 472 | Sep 22, 2023 | 214 | Jul 31, 2024 | 686 |
| -32.29% | Dec 18, 2020 | 69 | Mar 30, 2021 | 63 | Jun 29, 2021 | 132 |
| -28.39% | Jun 30, 2021 | 12 | Jul 16, 2021 | 29 | Aug 26, 2021 | 41 |
| -24.07% | Sep 22, 2021 | 7 | Sep 30, 2021 | 16 | Oct 22, 2021 | 23 |
| -6.57% | Dec 8, 2020 | 1 | Dec 8, 2020 | 7 | Dec 17, 2020 | 8 |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading data...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Cerevel Therapeutics Holdings, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Cerevel Therapeutics Holdings, Inc., comparing actual results with analytics estimates. In the past quarter, the company did not meet analyst expectations for EPS, resulting in a surprise of -19.7%.
Valuation
The Valuation section provides an overview of how Cerevel Therapeutics Holdings, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for CERE relative to other companies in the Biotechnology industry. Currently, CERE has a P/S ratio of 0.0. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for CERE in comparison with other companies in the Biotechnology industry. Currently, CERE has a P/B value of 14.5. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |